Zymeworks to Announce Q2 2024 Financial Results and Host August 1 Call

VANCOUVER, British Columbia, July 11, 2024 -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, is set to announce its financial results for the second quarter of 2024 after the market closes on August 1, 2024. Following the release, the management team will conduct a conference call and webcast to discuss the results and provide a corporate update at 4:30 pm Eastern Time.

Zymeworks Inc. is engaged in the discovery, development, and commercialization of innovative, multifunctional biotherapeutics aimed at improving treatment options for challenging diseases. The company's mission is to significantly impact the lives of individuals suffering from hard-to-treat cancers and other serious conditions. Utilizing complementary therapeutic platforms and an integrated drug development approach, Zymeworks focuses on precisely engineering and developing unique antibody-based therapeutic candidates.

One of the key developments from Zymeworks is zanidatamab, a HER2-targeted bispecific antibody created using the company's proprietary Azymetric™ technology. Zanidatamab is designed to target HER2-expressing cancers and is being tested in numerous global clinical trials as a potential leading treatment. Zymeworks has formed partnerships with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting them exclusive rights to develop and market zanidatamab in different regions.

A Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) for zanidatamab, seeking accelerated approval for its use in treating previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). The FDA has accepted the application and granted a Priority Review status. Additionally, another BLA has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would become the first HER2-targeted treatment specifically approved for BTC in both the U.S. and China.

Zymeworks is also progressing with a robust pipeline of product candidates, leveraging its expertise in antibody-drug conjugates and multispecific antibody therapeutics. The company's pipeline targets various novel indications that address significant unmet medical needs. Beyond its own product pipeline, Zymeworks' therapeutic platforms have been extended through strategic collaborations with major global biopharmaceutical firms.

Zymeworks' dedication to advancing biotherapeutic research and development positions it as a key player in the biotechnology sector, with a focus on providing innovative solutions and improving patient outcomes for those affected by serious diseases.